Article
N348I in HIV-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combination with other resistance mutations.
AIDS (London, England) - 16 Jan 2010
Sluis-Cremer Nicolas, Moore Katie, Radzio Jessica, Sonza Secondo, Tachedjian Gilda
Abstract excerpt
We previously demonstrated that N348I in HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. However, both of these inhibitors are currently infrequently used in developed countries, and the impact of N348I on newer reverse transcriptase inhibitors, such as tenofovir and etr...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
